Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Advanced Therapies Week 2022 | MOMENTUM: ARU-1801 in sickle cell disease

Will Chou • 26 Jan 2022
Advanced Therapies Week 2022
Sickle Cell Disease ARU-1801
MOMENTUM

Will Chou, MD, Aruvant, New York, NY, presents preliminary results from the Phase I/II MOMENTUM study (NCT02186418) of ARU-1801, a lentiviral gene therapy, in patients with sickle cell disease (SCD). 5 patients are currently enrolled and the investigational therapy has a promising efficacy and safety profile, with no vaso-occlusive episodes (VOE) or hospital stays reported in patients. Dr Chou additionally reports a durable response in patients, with therapeutic hemoglobin detected in patients 3 years after initial administration. This interview took place at Advanced Therapies Week 2022.

Disclosures

Will Chou, MD, is an employee of Aruvant.

More from Will Chou

2:04
Optimizing patient access and development costs of gene therapies
Will Chou • 27 Jan 2022
1:06
Increasing patient recruitment to rare disease trials
Will Chou • 26 Jan 2022
2:26
ARU-1801, a novel lentiviral gene therapy for SCD
Will Chou • 27 Jan 2022
1:10
Addressing issues in conducting clinical trials for rare diseases
Will Chou • 27 Jan 2022

Related Videos

1:06
Increasing patient recruitment to rare disease trials
Will Chou • 26 Jan 2022
2:26
ARU-1801, a novel lentiviral gene therapy for SCD
Will Chou • 27 Jan 2022
1:10
Addressing issues in conducting clinical trials for rare diseases
Will Chou • 27 Jan 2022
4:08
HSC gene editing: current approaches and remaining challenges
Valentina Vavassori • 27 May 2021
The content of VJRegenMed is intended for healthcare professionals